Tzar Labs and Epigeneres Biotech have jointly developed a new cancer  test, which is non-invasive, has diagnostic as well as prognostic value  and is easy to administer and scale up. They have conducted trials on a  large sample of 1000 cases and their test has worked very well.
Ashish  Tripathi of Tzar Labs and Anish Tripathi of   Epigeneres   spoke to Bharatvaarta about their innovation and answered many  questions posed specifically by medical professionals, which  Bharatvaarta had crowd-sourced.
The two  brothers are passionate about the social impact of an early cancer  diagnosis and prognosis - this not just helps families control their  medical expenses but also provides lifespan longevity to the impacted  patients. The test is named HrC and there is a deeply personal story  behind this, which was also covered by the Tripathi brothers.
Ashish  has been an investment banker working across multiple countries while  Anish is a supply chain expert and consultant, also with extensive  global and India expertise. They plan to launch the test in India first,  although this has a huge global impact.
Will  an Indian innovation in healthcare leave a lasting impact on the way the  world fights with cancer? Hear from the two individuals who may be at  the cusp of making history.